SeekIn and OncoInv have joined forces to make multi-cancer early detection (MCED) accessible in low- and middle-income countries (LMICs). SeekIn has developed several blood-based solutions to simplify and enhance cancer diagnosis and analysis. This technology can be easily adopted in many countries to increase early detection, leveraging existing medical infrastructure to benefit patients who will have access to quicker and less painful means of screening for cancer. SeekIn and OncoInv are collaborating to make this technology available to as many people as possible at low cost.

A revolution in cancer diagnosis

SeekIn products are based on blood samples and require no biopsy or imaging equipment, making them a non-invasive and patient-friendly solution. OncoSeek® was specifically designed as an affordable and effective screening tool that is expected to be widely used in LMICs.

How it works

Blood samples are analysed for a selected number of Protein Tumour Markers (PTM). The resulting data are processed by SeekIn’s cloud-based software using Machine Learning (ML) and big data to distinguish cancer patients from non-cancer individuals. The algorithm, operated by OncoInv, is fully GDPR compliant.

This MCED test covers the most common aggressive cancers and shows significantly reduced false positive rates compared with traditional clinical approaches in the realm of early detection and diagnosis.

By utilising machine learning, OncoSeek® offers simple and improved PTM-based early detection for all aggressive cancers at low cost, making it suitable for LMICs. The test makes use of existing medical infrastructure therefore no big investments are needed. The methodology and clinical effectiveness of OncoSeek were published in eClinicalMedicine, a clinical journal published by The Lancet, with DOI in July 2023.

Joining forces for the benefit of patients

SeekIn and OncoInv are collaborating to support the roll-out of this technology in as many countries as practicable and they will offer the products at low cost to make them affordable for as many people as possible.

About OncoInv

OncoInv is a newly-formed company based in Houten, The Netherlands . The mission of OncoInv is to make multi-cancer early detection solutions available to as many people as possible, thus improving potential prognosis outcomes for them and their families. OncInv offers its products and services on a not-for-profit basis in LMICs to ensure high availability by keeping costs to a minimum. OncoInv is a fully-owned subsidiary of Inspire2Live.  For more information you can visit www.oncoinv.org.

About SeekIn

SeekIn is a biotech company founded in early 2018 in Shenzhen, China, which focuses on blood-based pan-cancer early detection utilising next-generation sequencing and machine learning. Since its creation, SeekIn has been committed to providing cutting-edge and cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation. SeekIn also developed novel molecular tests for leukaemia patients and its cancer early detection technology has been successfully applied to canines. With its proprietary technical advances, SeekIn has launched a number of research and clinical studies in collaboration with top-tier hospitals in China. SeekIn envisions that by leading a new norm for cancer early detection the clinical outcome of mid-/late-stage cancer patients can be reversed and the cancer mortality rate can be reduced by 15%. For more information about SeekIn’s cutting-edge technologies and products, visit www.seekincancer.com. SeekIn lt is a fully-owned US-based entity of SeekIn.

About Inspire2Live

Inspire2Live is an patient advocacy organisation operating on an international level. We are on a mission to inspire and empower patients, researchers and clinicians to work together to prevent, treat and eliminate cancer. If we all believe that healthcare should be for the benefit of patients, then we should be part of the discussion and the decision process: When about us, not without us. We achieve our goals by connecting stakeholders in the medical industrial complex and organising congresses and discovery networks. These connections have led to many initiatives which are transforming the way research and healthcare work to become more patient-centric. We operate globally in full respect of local considerations. For more information, please continue your visit on our website www.inspire2live.org.